Trial · NCT07896460
A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
NCT07896460, Phase 1, Not yet recruiting, BeOne Medicines
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors. Trials, record NCT07896460. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896460
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
- NCT number
- NCT07896460
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 137 participants, estimated
- Lead sponsor
- BeOne Medicines
- Conditions
- Advanced Solid Tumor
- Interventions
- BG-92505, Anti-Cancer Agent
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Dose-Limiting Toxicities (DLTs) | Approximately 1 month | |
| Primary | Number of Participants with Treatment-emergent Adverse Events, Treatment-related Adverse Events, and Serious Adverse Events | Approximately 24 months | An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment, whether considered related to study treatment or not. A serious adverse event is any untoward medical occurrence that, at any dose, meets one or more of the criteria listed in the view of either the investigator or the Sponsor: 1. Results in death 2. Is life-threatening 3. Requires inpatient hospitalization or prolongation of existing hospitalization 4. Results in persistent or significant disability/incapacity 5. Is a congenital anomaly/birth defect |
| Secondary | Objective Response Rate (ORR) | Approximately 24 months | ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors (RECIST) 1.1 assessed by the investigator. |
| Secondary | Duration of response (DOR) | Approximately 24 months | DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Disease Control Rate (DCR) | Approximately 24 months | DCR is defined as the percentage of participants with BOR of CR, PR, or stable disease, as assessed by the investigator. |
| Secondary | Progression-free Survival (PFS) | Approximately 24 months | PFS is defined as the time from the date of the first administration of study treatment to the date of the first documentation of disease progression assessed by the investigator according to RECIST 1.1 or death due to any cause, whichever occurs first. |
| Secondary | Plasma concentrations of BG-92505 | Predose and postdose, up to approximately 6 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896460
GET https://conductscience.org/api/trials/v1/NCT07896460/registered